Outsee raises 1.8m for AI genomics in drug discovery
Longevity Technology - 25-Jun-2025Nomaly uses AI to decode disease from genomes, enabling precision medicine with small datasets
Join the club for FREE to access the whole archive and other member benefits.
Contributing editor to Longevity Technology
Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Details last updated 10-Feb-2020
Nomaly uses AI to decode disease from genomes, enabling precision medicine with small datasets
Tech screens 1,000s of antibodies per assay; links chronic inflammation to faster ageing
New platform aims to cut drug discovery by $2B and 9 years using lab-grown human immune models
AI-driven protein therapies aim to boost muscle health and metabolism alongside weight loss
Ro5’s AI platform boosts Juvenescence’s age-related drug pipeline and fuels UAE healthtech push
Biotech firm uses AI and robotics to test drugs on real human tissues, not animals
The company is still in early stages but attracting strong investor interest
Dorian’s anti-senescence tech adds firepower to Altos Labs’ rejuvenation strategy
Somite AI uses DeltaStem to speed up and scale stem cell engineering
Private funding supports global scientists tackling Alzheimer’s, vision loss, and glaucoma
Biotech startup raises $65M to develop RNA therapies that reprogram disease-driving cell states
AI-driven health platform gears up for launch with cutting-edge longevity data
The biotech company aims to target the root causes of ageing to develop therapies to extend lifespan
HepaRegeniX advances trials for a novel liver regeneration therapy
A next-gen retinal implant offers new hope for vision loss from macular degeneration
It avoids common delivery problems and enters Phase 1 trials in 2025
Scandinavian biotech targets fibrosis with novel scar-blocking therapies
It uses blood tests to find early health risks and gives personalised advice
Clinical trials are beginning, backed by major investors like Novo Holdings
Targeted protein degradation tackles harmful aggregates while sparing healthy proteins